iBio, Inc. (NASDAQ:IBIO) Given Average Rating of "Buy" by Analysts

Key Points

• Analysts rate iBio “Buy” overall: Of eight firms covering the stock, four recommend buying and three give a strong-buy rating, while one rates it a sell. The average 12-month price target is $5.00, with individual targets ranging from $5 to $6.
• iBio remains unprofitable and recently missed estimates: The company reported a quarterly loss of $0.07 per share versus the $0.06 consensus estimate, and analysts expect a full-year loss of $0.36 per share.
• The stock trades well below its analyst targets: Shares opened at $1.41, compared with a 12-month range of $0.56 to $3.82; institutional investors own 7.9% of the company.

iBio, Inc. (NASDAQ:IBIO - Get Free Report) has been assigned a consensus rating of "Buy" from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $5.00.

IBIO has been the topic of several analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of iBio in a report on Wednesday, June 24th. Chardan Capital restated a "buy" rating and set a $5.00 price target on shares of iBio in a report on Thursday, July 2nd. Raymond James Financial assumed coverage on shares of iBio in a research report on Monday, June 8th. They issued an "outperform" rating and a $5.00 price target on the stock. B. Riley Financial started coverage on shares of iBio in a research note on Friday, June 5th. They issued a "buy" rating and a $6.00 price objective on the stock. Finally, Wall Street Zen cut shares of iBio from a "hold" rating to a "sell" rating in a research report on Sunday, July 12th.

iBio Trading Up 1.4%

Shares of IBIO opened at $1.41 on Friday. The company has a market capitalization of $70.05 million, a PE ratio of -2.43 and a beta of 1.30. iBio has a 12 month low of $0.56 and a 12 month high of $3.82. The stock's 50-day moving average price is $1.57 and its two-hundred day moving average price is $1.92.

iBio (NASDAQ:IBIO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Equities research analysts predict that iBio will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On iBio

Several institutional investors and hedge funds have recently made changes to their positions in IBIO. Boothbay Fund Management LLC boosted its holdings in shares of iBio by 10.9% during the 3rd quarter. Boothbay Fund Management LLC now owns 176,862 shares of the company's stock worth $146,000 after buying an additional 17,414 shares in the last quarter. PFG Investments LLC bought a new stake in shares of iBio in the 4th quarter valued at $41,000. XTX Topco Ltd bought a new stake in shares of iBio in the 4th quarter valued at $71,000. State Street Corp lifted its position in shares of iBio by 116.3% during the 4th quarter. State Street Corp now owns 72,899 shares of the company's stock valued at $141,000 after acquiring an additional 39,200 shares during the period. Finally, Persistent Asset Partners Ltd acquired a new position in shares of iBio during the 4th quarter valued at $76,000. Institutional investors own 7.90% of the company's stock.

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source